One relatively safe bet about how Pfizer's lineup will look different five years from now is that the company will be a ...

Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

Pfizer Inc. today announced that after a comprehensive internal and external selection process, the company is appointing Chris Boshoff, M.D., PhD, as Chief Scientific Officer and President ...

This agreement solidifies Pfizer at the forefront of innovative cancer research and further enhances the company’s robust oncology pipeline. “We are excited to contribute our significant expertise and ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

BioNTech SE and Pfizer (PFE) recently received a positive recommendation from the European Medicines Agency for marketing ...

Genmab (Otc) (($GMAB)) announced an update on their ongoing clinical study. Pfizer Inc. and Genmab are conducting a Phase 4 ...

Pfizer elevated Dr. Chris Boshoff, MD, PhD to serve as chief scientific officer as well as research and development president on Wednesday morning. Boshoff, who has been with Pfizer for more than 11 ...

(Reuters) -Pfizer said on Wednesday it has named company veteran and oncology head Chris Boshoff as its chief of research and development, as the drugmaker faces pressure from investors to produce ...

Pfizer’s Oncology R&D organization will maintain its fully integrated structure with Roger Dansey, M.D. serving as Interim Chief Oncology Officer, reporting to Dr. Boshoffeffective January 1, 2025.